Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.

Blood - 29 Apr 2010

Demchenko Yulia N, Glebov Oleg K, Zingone Adriana, Keats Jonathan J, Bergsagel P Leif, Kuehl W Michael

Abstract excerpt

Mutations involving the nuclear factor-kappaB (NF-kappaB) pathway are present in at least 17% of multiple myeloma (MM) tumors and 40% of MM cell lines (MMCLs). These mutations, which are apparent progression events, enable MM tumors to become less dependent on bone marrow signals that activate NF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD40 Antigens
Share to Deubiquitinating Enzyme CYLD
Share to Inhibitor of Apoptosis Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multiple Myeloma

Share to NF-kappa B p50 Subunit

Share to Proteasome Endopeptidase Complex

Share to TNF Receptor-Associated Factor 2

Share to Transmembrane Activator and CAML Interactor Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 20053756
DOI: 10.1182/blood-2009-09-243535
PMCID: PMC2867265

Genes

TRAF2
TRAF3
CYLD
NFKB1
NFKB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-20053756-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.PMID 20053756Read ↗

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.Semantic proximity Read ↗

Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkBSemantic proximity Read ↗

Frequent Engagement of RelB Activation Is Critical for Cell Survival in Multiple MyelomaSemantic proximity Read ↗

Multiple myeloma: lusting for NF-kappaB.Semantic proximity Read ↗

Targeting NF-κB Signaling for Multiple MyelomaSemantic proximity Read ↗

Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation.Semantic proximity Read ↗

NF-kappaB in the pathogenesis and treatment of multiple myeloma.Semantic proximity Read ↗

WITHDRAWN: Canonical NF-κB regulator CYLD mutations reinforce RelB mediated disease pathogenesis in Multiple MyelomaSemantic proximity Read ↗

NF-κB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors.Semantic proximity Read ↗

How to Reprogram Myeloma-Associated Macrophages: Target IKZF1.Semantic proximity Read ↗

Kinase domain activation through gene rearrangement in multiple myeloma.Semantic proximity Read ↗

Identification of primary MAFB target genes in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.